Cidara Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDCidara Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings contraction of 30% provides fundamental context to the price action. However, with RSI at 85, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $220.70 | +0.31% | ABOVE |
| 50 SMA | $190.07 | +16.47% | ABOVE |
| 100 SMA | $136.15 | +62.60% | ABOVE |
| 150 SMA | $107.21 | +106.49% | ABOVE |
| 200 SMA | $85.66 | +158.44% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CDTX in an uptrend right now?
CDTX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CDTX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CDTX overbought or oversold?
CDTX's RSI (14) is 85. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CDTX outperforming the market?
CDTX has a Relative Strength (RS) Rating of 98 out of 99. Yes, CDTX is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is CDTX in its 52-week range?
CDTX is trading at $221.38, which is 100% of its 52-week high ($221.42) and 100% above its 52-week low ($15.22).
How volatile is CDTX?
CDTX has a Beta of 0.65 and 52-week volatility of 66%. It's less volatile than the S&P 500 - generally more stable.